IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Saved in:
| Title: | IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. |
|---|---|
| Authors: | Hack SP; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA., Verret W; Genentech, South San Francisco, CA, USA., Mulla S; Hoffmann-La Roche Limited, Mississauga, ON, Canada., Liu B; Genentech, South San Francisco, CA, USA., Wang Y; Genentech, South San Francisco, CA, USA., Macarulla T; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Ren Z; Zhongshan Hospital, Fudan University, Shanghai, China., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., Zhu AX; Massachusetts General Hospital Cancer Center, Boston, MA, USA. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2021 Jul 31; Vol. 13, pp. 17588359211036544. Date of Electronic Publication: 2021 Jul 31 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
